Insight Molecular Diagnostics (IMDX) Invested Capital (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Invested Capital data on file, last reported at -$10.5 million in Q1 2026.

• Quarterly Invested Capital fell 196.32% year-over-year to -$10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.5 million (down 196.32% YoY) and the FY2025 annual result came in at -$31.0 million, down 157.65% from the prior year.
• Invested Capital rose to -$10.5 million in Q1 2026 per IMDX's latest filing, from -$31.0 million in the prior quarter.
• The five-year high for Invested Capital was $83.9 million in Q2 2022, with the low at -$31.0 million in Q4 2025.
• Average Invested Capital over 5 years is $22.9 million, with a median of $22.8 million recorded in 2023.
• Year-over-year, Invested Capital retreated 5.64% in 2025 and plunged 196.32% in 2026.
• Insight Molecular Diagnostics' Invested Capital stood at $34.4 million in 2022, then plunged by 33.78% to $22.8 million in 2023, then sank by 152.88% to -$12.0 million in 2024, then plunged by 157.65% to -$31.0 million in 2025, then surged by 66.07% to -$10.5 million in 2026.
• Business Quant data shows IMDX's Invested Capital at -$10.5 million in Q1 2026, -$31.0 million in Q4 2025, and -$8.1 million in Q3 2025.